Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials

Targeted therapies such as oral tyrosine kinase inhibitors (TKIs) are the main therapeutic strategy effective for advanced hepatocellular carcinoma (HCC). Currently six tyrosine kinase inhibitors for HCC therapy have been approved. The newly approved first-line drug donafenib represent the major mil...

Descripción completa

Detalles Bibliográficos
Autores principales: Mou, Lisha, Tian, Xiaohe, Zhou, Bo, Zhan, Yongqiang, Chen, Jiao, Lu, Ying, Deng, Jing, Deng, Ying, Wu, Zijing, Li, Qi, Song, Yi’an, Zhang, Hongyuan, Chen, Jinjun, Tian, Kuifeng, Ni, Yong, Pu, Zuhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543014/
https://www.ncbi.nlm.nih.gov/pubmed/34707994
http://dx.doi.org/10.3389/fonc.2021.752725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543014/
https://www.ncbi.nlm.nih.gov/pubmed/34707994
http://dx.doi.org/10.3389/fonc.2021.752725

Ejemplares similares